Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.
Strong J, Kruger D, and Novak L. Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes. Curr Med Res Opin 2017:1-19.
Current medical research and opinion
Insulin glargine 300 units/mL: Insulin glargine 300 units/mL (Gla-300) is a formulation of insulin glargine that delivers the same number of insulin units in one-third of the injectable volume of insulin glargine 100 units/mL (Gla-100). Glucose control: Recently approved in the United States and in Europe for use in type 1 and type 2 diabetes, Gla-300 has a more constant and evenly distributed glucose-lowering effect compared with Gla-100, with a duration of action beyond 24 hours and lower within-day and between-day intra-individual variability in blood glucose levels. These benefits translate into predictable and sustained glucose control from a once-daily injection, with potential for fewer hypoglycemia episodes and less weight gain.
CASE STUDIES: Case studies are presented to highlight the potential clinical benefits and considerations associated with initiating treatment with Gla-300 in people with type 1 and type 2 diabetes.
Medical Subject Headings
Diabetes Mellitus; Drug Monitoring; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Treatment Outcome